Biomarker ID | 1412 |
PMID | 24740842 |
Year | 2014 |
Biomarker | CDON [SNP: rs3737336: CC] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate: Cohort 1: [1.75 (95% CI: 1.01–3.04))]; Cohort 1+2: [1.66 (95% CI: 1.13–2.43)]HR: Multivariate: Cohort 1: [2.03 (95% CI: 1.08–3.81)]; Cohort 2: [1.83 (95% CI: 1.03–3.22)]; Cohort 1+2: [1.91 (95% CI: 1.25–2.91)] |
Effect on Pathways | Pathways include: Signaling events mediated by the hedgehog family, CDO in myogenesis, Hedgehog signaling pathway, Developmental biology |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | two independent cohorts composed of 320 Asian and 526 Caucasian men with pathologically organ-confined prostate cancer were selected |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003 |
Method Used | MALDI-TOF |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |